Background
==========

Arterial thromboembolic events may be caused by arterial thrombosis, which is the formation of a thrombus within an artery. Arterial thrombosis is closely related to arterial diseases such as ischemic stroke and myocardial infarction \[[@b1-medscimonit-22-4345]\]. According to the American Heart Association, stroke is a fatal cerebrovascular disease and the leading cause of death and disability in the United States. In Korea, stroke is the second most common cause of death, and in 2014 it accounted for 50.3 deaths per 100 000 people aged over 65 years, according to Statistics Korea \[[@b2-medscimonit-22-4345]\]. The age-standardized incidence of ischemic stroke in the population of people aged 35--74 years has been increasing annually, and ischemic stroke accounted for 76% of all cases of strokes in 2009, with a 90-day mortality rate of 3--7% \[[@b3-medscimonit-22-4345]\]. Statistics Korea also reported 19.6 deaths due to myocardial infarction per 100 000 people in Korea in 2012 (*<http://kostat.go.kr>*).

Many pro-inflammatory cytokines are known to be involved in the risk of myocardial infarction and stroke. Cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) could play important roles in stroke and have been detected in the cerebrospinal fluid of patients with stroke \[[@b4-medscimonit-22-4345]\]. Several studies have suggested that plasma levels of TNF-α and IL-6 are associated with patient prognosis following ischemic stroke \[[@b5-medscimonit-22-4345]\]. Associations between IL-6 and atherosclerosis and cardiovascular disease have also been previously reported \[[@b6-medscimonit-22-4345]\]. Additionally, previous epidemiological data have shown that IL-6 is associated with clinical and subclinical cardiovascular diseases \[[@b7-medscimonit-22-4345]\]. IL-6 plays a major role in the synthesis of human acute-phase protein, and plasma IL-6 levels are elevated in patients with acute myocardial infarction \[[@b8-medscimonit-22-4345]\]. A previous *in vivo* study found that IL-lβ stimulates myocardial injury after IL-6 is induced in endothelial cells and fibroblasts \[[@b9-medscimonit-22-4345]\]. IL-6 induces a prothrombotic state by increasing expression of tissue factor, activation of endothelial cells, and increasing platelet production, and by reducing the levels of inhibitors of hemostasis \[[@b10-medscimonit-22-4345]\].

*IL-6* gene is located at 7p21 and encodes a cytokine that plays a role in inflammation and B cell maturation (*<http://www.ncbi.nlm.nih.gov>*). Two single-nucleotide polymorphisms (SNPs), −174, G/C SNP and −572, G/C SNP have been identified in the promoter region of the *IL-6* gene, which might have an effect on IL-6 transcription and plasma IL-6 levels \[[@b11-medscimonit-22-4345]--[@b13-medscimonit-22-4345]\]. The rs1800795 polymorphism has been examined in many previous studies. An association between *Helicobacter pylori* infection and decreased high-density lipoprotein (HDL) levels could be transmitted through its genotype of the *IL-6* gene \[[@b14-medscimonit-22-4345]\]. In patients with type 2 diabetes, rs1800795 SNP of the *IL-6* gene is significantly related to increased risk of cardiovascular disease \[[@b15-medscimonit-22-4345]\]. In addition, rs1800795 SNP of the *IL-6* gene is related with autoimmune diseases such as systemic lupus erythematosus \[[@b16-medscimonit-22-4345]\], systemic sclerosis \[[@b17-medscimonit-22-4345]\], and autoimmune thyroid disease \[[@b18-medscimonit-22-4345]\].

Although several previous studies have investigated the association between rs1800795 polymorphism and ischemic stroke or myocardial infarction risk, these results remain controversial. As the evidence suggests that IL-6 plays a major role in thromboembolic mechanisms, the aim of this meta-analysis was to evaluate the association between rs1800795 polymorphism (−174, G/C) of the *IL-6* gene and arterial thromboembolic events.

Material and Methods
====================

Search strategy
---------------

For the meta-analysis, we searched for published studies that considered the relationship between arterial thromboembolic events and polymorphism of the *IL-6* gene. To identify all eligible studies that investigated the association between −176, G/C SNP of the *IL-6* gene and susceptibility of arterial thromboembolic events, we performed a literature search in PubMed, Embase, Google Scholar, and Korean Studies Information Service System (KISS) electronic databases until January 1, 2016. The search terms were; "interleukin-6", "IL-6", or "IL6", AND "polymorphism", "polymorphisms", or "variant" AND "rs1800795", or"−174" AND "ischemic stroke", "myocardial infarction". We also searched previous meta-analyses of *IL-6* gene polymorphism (−174, G/C polymorphism) and ischemic stroke or myocardial infarction.

Inclusion criteria
------------------

Studies were included if they met the following criteria: (1) evaluated the association between the *IL-6* polymorphism (−174, G/C) and ischemic stroke or myocardial infarction; (2) study design using the methodology of a case-control study; (3) complete distribution of polymorphism (−174, G/C) of the *IL-6* gene in the disease group and the control group to determine odds ratio (OR), 95% confidence interval (CI), and *P* value; (4) only studies in white populations were included, and studies of Asian populations were excluded.

Data extraction
---------------

Two investigators independently searched titles and abstracts in articles. Irrelevant and incompatible studies were excluded. The investigators extracted data and reached consensus on all of the items. If the investigators generated different results, they checked the data again and had a discussion to come to an agreement. The following information were extracted from each study: (1) first author's name; (2) year of publication; (3) country; (4) number of cases and controls; (5) genotype frequency of *IL-6* gene polymorphism (−174, C/G).

Statistical analysis
--------------------

Comprehensive meta-analysis software (Corporation, NJ) was used to perform the meta-analysis. The pooled OR, 95% CI, and *P* value were used to measure associations between susceptibility of arterial thromboembolic events and IL-6 polymorphism (−174, G/C). Firstly, we calculated the heterogeneity of studies. Heterogeneity among studies was assessed using the Q statistic and *I^2^* test. When the result of the Q test was *P*\<0.05 or *I^2^* statistic was \>50%, the random-effects Mantel-Haenszel method was used to determine if there was significant heterogeneity between studies. When the result of the Q test was *P*\>0.05 or *I^2^* statistic was \<50%, the fixed-effects Mantel-Haenszel method was used.

For meta-analysis of *IL-6* gene polymorphism (−174, C/G), the pooled ORs, 95% CI, and p value were calculated using combination of genotype. We first estimated the risks of "C allele *vs*. G allele", "C/C genotype+C/G genotype *vs*. G/G genotype", and "C/C genotype *vs*. C/G genotype+G/G genotype" on arterial thromboembolic events, assuming dominant and recessive effects of the variant C allele, respectively. Subgroup analyses were carried out by ischemic stroke or myocardial infarction. The *P*\<0.05 was regarded as a statistically significant association.

Results
=======

Study characteristics
---------------------

To assess the association between polymorphism (−174, G/C) of *IL-6* gene and susceptibility to arterial thromboembolic events, related studies were retrieved based on the search strategy. First, we searched related studies on arterial thromboembolic events including ischemic stroke and myocardial infarction. Our meta-analysis was limited to case-control design with promoter polymorphism (−174, G/C) of the *IL-6* gene and ischemic stroke or myocardial infarction in white populations. Although 6 articles were studied with polymorphism (−174, G/C) of *IL-6* gene and susceptibility of ischemic stroke or myocardial infarction in Asian populations \[[@b19-medscimonit-22-4345]--[@b24-medscimonit-22-4345]\], the articles were excluded in the meta-analysis. Finally, 13 eligible articles were selected \[[@b25-medscimonit-22-4345]--[@b37-medscimonit-22-4345]\]. The characteristics of these 13 eligible studies are summarized in [Table 1](#t1-medscimonit-22-4345){ref-type="table"}. The 13 studies consisted of 6 articles on ischemic stroke and 7 articles on myocardial infarction.

Quantitative synthesis for arterial thromboembolic events
---------------------------------------------------------

[Table 2](#t2-medscimonit-22-4345){ref-type="table"} and [Figure 1](#f1-medscimonit-22-4345){ref-type="fig"} shows overall results between *IL-6* gene polymorphism (−174, G/C) and susceptibility to arterial thromboembolic events. We analyzed whether risk of the C allele and combined genotype of the SNP were related with susceptibility of arterial thromboembolic events. The results of the Q test were *P* value or *I2*statistic in analysis of C allele *vs*. G allele, CC genotype *vs*. CG genotype+GG genotype, and CC genotype+CG genotype *vs*. GG genotype were \<0.05 and \>50%, the random-effects Mantel-Haenszel method was used ([Table 2](#t2-medscimonit-22-4345){ref-type="table"}). In analysis, the pooled ORs and *P* value in allele model and combined genotype models did not show any significant association with susceptibility of arterial thromboembolic events (C allele *vs*. G allele, OR=1.04, 95% CI=0.91--1.19, *P*=0.619; CC genotype *vs*. CG genotype+GG genotype, OR=1.09, 95% CI=0.91--1.31, *P*=0.364; CC genotype+CG genotype *vs*. GG genotype, OR=0.97, 95% CI=0.78--1.21, *P*=0.763, respectively) ([Table 1](#t1-medscimonit-22-4345){ref-type="table"}, [Figure 1](#f1-medscimonit-22-4345){ref-type="fig"}).

We also performed subgroup analyses of ischemic stroke and myocardial infarction. However, *IL-6* gene polymorphism (−174, G/C) did not show any significant association with ischemic stroke (C allele *vs*. G allele, OR=0.99, 95% CI=0.70--1.40, *P*=0.930; CC genotype *vs*. CG genotype+GG genotype, OR=0.99, 95% CI=0.70--1.39, *P*=0.929; CC genotype+CG genotype *vs*. GG genotype, OR=0.98, 95% CI=0.50--1.92, *P*=0.931, respectively) ([Table 2](#t2-medscimonit-22-4345){ref-type="table"}, [Figure 2](#f2-medscimonit-22-4345){ref-type="fig"}) and myocardial infarction (C allele *vs*. G allele, OR=1.07, 95% CI=0.94--1.22, *P*=0.319; CC genotype *vs*. CG genotype+GG genotype, OR=1.17, 95% CI=0.93--1.46, *P*=0.187; CC genotype+CG genotype *vs*. GG genotype, OR=0.99, 95% CI=0.88--1.11, *P*=0.778, respectively) ([Table 2](#t2-medscimonit-22-4345){ref-type="table"}, [Figure 3](#f3-medscimonit-22-4345){ref-type="fig"}).

To assess publication bias, Begg's funnel plot was used out and Egger's test was calculated. The funnel plot was symmetrical (data not shown), suggesting that there was no publication bias. Additionally, Egger's test showed quantitative evidence for absence of publication bias (*P*\>0.05 in each model, [Table 2](#t2-medscimonit-22-4345){ref-type="table"}).

Discussion
==========

According to Statistics Korea, stroke and cardiovascular diseases were among the top 10 causes of death in Korea in 2014. Among them, stroke is the number 2 cause of death (*<http://kostat.go.kr>*). According to the Korea National Emergency Medical Center in 2014, a total of 26 208 patients visited emergency departments due to myocardial infarction and 430 patients died. A total of 91 924 stroke patients visited emergency departments due to stroke and 451 patients died in 2013 (*<http://www.nemc.or.kr>*). These diseases cause death and disability, creating burdens for patients, their families, society, and the world \[[@b3-medscimonit-22-4345]\].

Therefore, there have been many attempts to predict or prevent these diseases. C-reactive protein (CRP) and creatinine in serum are used to predict coronary heart disease risk \[[@b38-medscimonit-22-4345]\]. Red blood cell distribution width and calcium score can be used to assess cardiovascular event risk stratification and prevention \[[@b39-medscimonit-22-4345]\]. Some authors developed risk scoring system for prediction of atypical symptom presentation in acute myocardial infarction patients \[[@b40-medscimonit-22-4345]\]. Increase in the systemic inflammatory marker procalcitonin is related to no-reflow after primary percutaneous coronary intervention in ST-elevation myocardial infarction patients \[[@b41-medscimonit-22-4345]\]. Hemorheological abnormalities, poor glycemic control, and low HDL cholesterol are used as markers and predictors for major adverse cardiovascular events and coronary heart disease in outpatients \[[@b42-medscimonit-22-4345]\]. The ankle-brachial index is useful in predicting acute ischemic stroke \[[@b43-medscimonit-22-4345]\].

Recently, many studies have reported the genetic contribution to predict or prevent these diseases. Several studies showed the genetic contribution to inflammatory and hemostatic biomarkers in ischemic stroke patients \[[@b44-medscimonit-22-4345]\]. *CYP2C19* gene polymorphisms are associated with long-term recurrent risk of ischemic stroke \[[@b45-medscimonit-22-4345]\]. Peroxisome proliferator-activated receptors could be a protective factor for ischemic stroke in the Chinese Han population \[[@b46-medscimonit-22-4345]\]. A previous study showed that genetic factors are associated with age at stroke onset and sex \[[@b47-medscimonit-22-4345]\]. Gene-specific DNA methylation profiles and LINE-1 hypomethylation are associated with myocardial infarction risk \[[@b48-medscimonit-22-4345]\]. Recently, there was an attempt to find predictors of myocardial infarction using genotype/allelic combinations by analysis of genotype frequencies of polymorphic markers \[[@b49-medscimonit-22-4345]\].

Inflammatory cytokines in arterial lesions plays various roles, including plaque formation and progression and vessel thrombosis \[[@b50-medscimonit-22-4345]\]. Cytokines produce adhesion molecules, matrix metalloproteinases, and reactive oxygen species and induce the expression of the messenger cytokine IL-6, which causes the release of C-reactive protein, fibrinogen, and plasminogen activator inhibitor-1. These lead to atherothrombosis, which is the proximate cause of arterial thrombosis \[[@b51-medscimonit-22-4345]\]. The genotype of IL-6 is also involved in this process. The IL-6 genotype was significantly associated with thrombosis in children \[[@b52-medscimonit-22-4345]\] and increased risk of ischemic stroke \[[@b53-medscimonit-22-4345]\].

Therefore, we performed this meta-analysis to examine the possible association between IL-6 rs1800795 polymorphism and ischemic stroke and myocardial infarction risks. However, we found no statistically significant association between the IL-6 rs1800795 polymorphism and ischemic stroke or myocardial infarction risks in any models.

In the present study, we collected previous studies on ischemic stroke or myocardial infarction and IL-6 polymorphism and could not find any associations. Our results agree with a previous meta-analysis in 2012, which reported a significant association between IL-6 gene −174 G/C polymorphism and myocardial infarction risk in Asians but not in whites \[[@b54-medscimonit-22-4345]\]. As there were few studies on Asians, we included only studies on whites and found no association. A previous study showed that pro-inflammatory and prothrombotic polymorphisms, including IL-6, were not associated with perinatal arterial ischemic stroke \[[@b55-medscimonit-22-4345]\].

Conclusions
===========

It is clear that IL-6 plays an important role in the initiation of thrombosis, resulting in ischemic stroke or myocardial infarction. However, we could not show any statistical significance in the models. It appears that IL-6 rs1800795 is not associated with ischemic stroke or myocardial infarction risk. Further studies including clinical features are needed to clarify the possible relationship between IL-6 rs1800795 polymorphism and the development of ischemic stroke or myocardial infarction.
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###### 

Information of eligible studies included in the meta-analysis.

  Study                      Country   Disease   Case/control (n)   Case   Control   Case   Control   HWE in Control                                    
  -------------------------- --------- --------- ------------------ ------ --------- ------ --------- ---------------- ----- ------ ------ ----- ------ ------
  Revilla et al. (2002)      Spain     IS        82/82              15     40        27     6         39               37    70     94     51    113    0.32
  Balding et al. (2004)      Ireland   IS        105/389            12     60        33     68        198              123   84     126    334   444    0.45
  Flex et al. (2004)         Italy     IS        237/223            22     115       100    68        99               56    159    315    235   211    0.10
  Chamorro et al. (2005)     Spain     IS        273/105            35     134       104    9         50               46    204    342    68    142    0.37
  Lalouschek et al. (2006)   Austria   IS        404/415            74     187       143    67        192              156   335    473    326   504    0.54
  Bazina et al. (2015)       Croatia   IS        114/187            22     53        39     26        98               63    97     131    150   224    0.21
  Georges et al. (2001)      France    MI        614/672            104    340       170    105       336              231   548    680    546   798    0.35
  Nauck et al. (2002)        Germany   MI        2575/729           261    668       436    144       355              230   1190   1540   643   815    0.74
  Licastro et al. (2004)     Italy     MI        138/97             15     88        35     7         44               46    118    158    58    136    0.42
  Lieb et al. (2004)         Germany   MI        1322/1023          244    627       451    193       499              331   1115   1529   885   1161   0.84
  Kelberman et al. (2004)    UK        MI        507/561            61     219       227    81        240              240   341    673    402   720    0.10
  Chiappelli et al. (2005)   Italy     MI        138/204            21     112       71     24        106              127   154    254    154   360    0.78
  Bennermo et al. (2011)     Sweden    MI        356/378            87     150       119    93        176              109   324    388    362   394    0.19

IS -- ischemic stroke; MI -- myocardial infarction; HWE -- Hardy-Weinberg equilibrium.

###### 

Overall analysis between interleukin-6 polymorphism (−174, G/C) and susceptibility of arterial thromboembolic events.

          Comparison       Heterogeneity   Model     Association test   Publication bias            
  ------- ---------------- --------------- --------- ------------------ ------------------- ------- -------
  IS+MI   C *vs.* G        \<0.001         80.941    Random             1.04 (0.91--1.19)   0.619   0.454
  IS      C *vs.* G        \<0.001         87.738    Random             0.99 (0.70--1.40)   0.930   0.642
  MI      C *vs.* G        0.002           70.814    Random             1.07 (0.94--1.22)   0.319   0.090
  IS+MI   CC *vs.* CG+GG   \<0.001         75.820    Random             1.09 (0.91--1.31)   0.364   0.321
  IS      CC *vs.* CG+GG   0.002           72.982    Random             0.99 (0.70--1.39)   0.929   0.734
  MI      CC *vs.* CG+GG   \<0.001         80.143    Random             1.17 (0.93--1.46)   0.187   0.080
  IS+MI   CC+CG *vs.* GG   \<0.001         71.398    Random             0.97 (0.78--1.21)   0.763   0.783
  IS      CC+CG *vs.* GG   \<0.001         86.953    Random             0.98 (0.50--1.92)   0.931   0.706
  MI      CC+CG *vs.* GG   0.827           \<0.001   Fixed              0.99 (0.88--1.11)   0.778   0.290

IS -- ischemic stroke; MI -- myocardial infarction; OR -- odds ratio; CI -- confidence interval.
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